Columbus Circle Investors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Columbus Circle Investors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-29,831	Closed	-$4.65M	–	193
2020 Q2	$4.65M	Sell	29,831 -16,585	-36%	-$2.52M	0.19%	130
2020 Q1	$6.7M	Sell	46,416 -7,167	-13%	-$1.38M	0.37%	100
2019 Q4	$11M	Buy	53,583 +46,817	+692%	+$8.54M	0.47%	84
2019 Q3	$543K	Sell	6,766 -2,489	-27%	-$211K	0.02%	149
2019 Q2	$873K	Sell	9,255 -541	-6%	-$46.7K	0.02%	154
2019 Q1	$837K	Sell	9,796 -8,887	-48%	-$738K	0.02%	142
2018 Q4	$1.05M	Sell	18,683 -18,439	-50%	-$1.13M	0.03%	143
2018 Q3	$3.04M	Buy	+37,122	New	+$2.62M	0.06%	160

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Columbus Circle Investors's RETA Position: Q3 2020 in Review

Columbus Circle Investors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 29,831 shares — an estimated $4.65M sold.

Columbus Circle Investors first reported a position in RETA in Q3 2018 and held it in 8 quarters. The position peaked at $11M in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

Columbus Circle Investors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
Columbus Circle Investors sold 29,831 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $4.65M.
Columbus Circle Investors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 8 quarters.
Columbus Circle Investors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $11M in Q4 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Columbus Circle Investors's 13F filing for Q3 2020, filed 27 Oct 2020.